Management of Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Researchers from the University of Wisconsin, Cornell, and a consortium of other institutions conducted a retrospective analysis on CD19-directed CAR T-cell therapy for R/R T-cell/histiocyte-rich LBCL.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

The CRL did not identify any deficiencies related to the manufacturing, efficacy, or safety outlined in the BLA, and no new clinical trials were requested.

Brentuximab vedotin, lenalidomide, and rituximab yielded a median OS of 13.8 months and a median PFS of 4.2 months in the phase 3 ECHELON-3 trial.